Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

NCT06552234 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV
NSCLC, Stage III

Interventions

DRUG: Repotrectinib

Sponsor

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Collaborators

[object Object]
[object Object]